Stargardt Disease clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 16 years and up
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.
San Francisco, California and other locations